Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02969291
Other study ID # 776553-5
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2016
Est. completion date October 2018

Study information

Verified date July 2019
Source Baystate Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is a well-documented association between physical activity & risk for breast cancer development and recurrence. It is known that exercise interventions have been effective at increasing physical activity levels in breast cancer survivors. Knowing that breast cancer survivors are less active than non-cancer patients, a less active lifestyle places them at risk of obesity and poor overall health, which in turn also increases risk of cancer and cancer recurrence. Not all the reasons for the risk reduction are clear, however it is known that hormones and other inflammatory markers play a role.

This study has three goals:

1. To investigate the feasibility of a home intervention designed to reduce sedentary behavior.

2. Describe the effects of the intervention on levels of sedentary behavior, physical activity, and symptoms.

3. Assess cost of the intervention.


Description:

There is a well-documented association between physical activity and risk for breast cancer development and recurrence. Exercise training interventions have been effective at increasing physical activity levels in breast cancer survivors, however they require 1) a large degree of patient initiative to achieve positive health outcomes associated with sustained behavioral change and 2) facilities and oversight that may be prohibitive in a clinical setting. Although most activity-based research to date has focused on increasing levels of moderate to vigorous physical activity (MVPA) for breast cancer survivors, large epidemiological studies suggest that breast cancer survivors are also more sedentary when compared to non-cancer controls. A recent meta-analysis of controlled intervention trials designed to promote physical activity among sedentary cancer survivors found that none of the trials within the scope of the review succeeded in achieving 75% or better adherence to prescribed exercise guidelines, leading the authors to question whether shifting the target of intervention from MVPA to reductions in sedentary time might be a more realistic goal. Recent research suggests that interventions designed to reduce sedentary time in breast cancer survivors have the potential to yield clinically meaningful health benefits, especially for individuals at higher risk for sedentary behaviors, however the optimal method of intervention is not clear.

Aim 1: Feasibility of the intervention Assess the feasibility of an intervention designed to reduce sedentary behavior in breast cancer survivors. The behavioral intervention will involve the review of a 7-day baseline snapshot of sedentary behavior and physical activity patterns, combined with tailored activity prompts described over the following 6 weeks.

Aim 2: Effects of the intervention Aim 2a: Describe a preliminary range of effect sizes of the intervention on levels of sedentary behavior, physical activity and symptoms of cancer survivorship (e.g. cancer related fatigue).

Aim 2b: Evaluate the relationship between change in sedentary behavior and change in cancer-relevant outcomes, such as fatigue and biomarkers of cancer recurrence (e.g. IGF-1, Leptin), following the reduced sedentary time intervention.

Aim 3: Assessment of intervention components Aim 3a: Quantitatively assess overall cost of the intervention and its individual components, dose delivered and dose received by intervention participants Aim 3b: Quantitatively describe intervention participants' perspectives on the impact of the individual intervention components, including which components appeared most useful for reducing sedentary time.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date October 2018
Est. primary completion date October 2018
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria:

- Stage I-III breast cancer survivors 20-80 who have completed primary treatment (surgery, radiation and/or chemotherapy) greater than 6 months but less than 5 years ago. Patients may be on adjuvant hormonal therapy

- BMI > 25 (overweight or class I/II obese)

- Not meeting current guidelines for regular exercise as defined by less than 150 minutes a week of moderate to vigorous physical activity

- No gain or loss of >10% body weight over the prior 6 months.

Exclusion Criteria:

- Known diabetes

- Known coronary artery disease

- Pregnancy

- Any injury that would limit mobility or require use of assisted mobility devices

- Weight gain or loss of >10% body weight over the prior 6 months

- Greater than 150 minutes a week of moderate to vigorous physical activity

- Inability to provide informed consent

- Non-english speaking

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Reduced Sedentary Time Intervention (RSTI)
Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.

Locations

Country Name City State
United States Baystate Medical Center Springfield Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Baystate Medical Center University of Massachusetts, Amherst

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sedentary Time Change in minutes/day of sedentary time as recorded by ActivPal in all 25 participants pre and post intervention. 8 weeks
Secondary Activity Level Change in Activity level as recorded by Actigraph monitor in all 25 participants 8 weeks
Secondary Glucose Change in fasting glucose ( mmol/L)in all 25 participants 8 weeks
Secondary Insulin Change in insulin (pmol/L) in all 25 participants 8 weeks
Secondary Total cholesterol Change in total cholesterol (mmol) in all 25 participants 8 weeks
Secondary High density lipoprotien cholesterol Change in high density lipoprotein cholesterol (mmol) in all 25 participants 8 weeks
Secondary Triglyceride Change in triglycerides (mmol) in all 25 participants 8 weeks
Secondary Body Mass Index Change in Body Mass Index (kg/m2) in all 25 participants 8 weeks
Secondary Waist Circumference Change in waist circumference in cm in all 25 participants 8 weeks
Secondary Systolic Blood pressure Change in systolic blood pressure measured in mmHg in all 25 participants 8 weeks
Secondary Diastolic Blood pressure Change in diastolic blood pressure measured in mmHg in all 25 participants 8 weeks
Secondary Cancer-related fatigue measured by change in PROMIS short form 8a in all 25 participants 8 weeks
Secondary Cancer-related fatigue as measured by change in Visual Analog scale in all 25 participants 8 weeks
Secondary Sedentary behavior self -efficacy Change in Sedentary Behavior Self-Efficacy Scale (modified from BARSE) in all 25 participants 8 weeks
Secondary Change in EORTC-QLQ-C30 scores in all 25 participants 8 weeks
Secondary Assessment of Intervention Change in Assessment of Intervention questions on a scale of 1-5 in all 25 participants 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2